Interspace Biosciences

Interpace Biosciences provides molecular diagnostic testing and pathology services that help physicians assess cancer risk in patients with indeterminate biopsies. Its current business centers on ThyGeNEXT and ThyraMIR v2, genomic tests used to further characterize thyroid nodules when cytopathology cannot establish whether a lesion is benign or malignant. The company serves physicians, hospitals, cancer centers, commercial laboratories, pathology groups and clinics, with LabCorp its largest thyroid-testing customer in 2025 and the first half of 2026. Revenue comes from Medicare, Medicare Advantage, Medicaid, commercial insurers and direct billing to institutional clients. Following the loss of CMS reimbursement, Interpace stopped accepting specimens for its PancraGEN pancreatic test after May 2, 2025, increasing its reliance on thyroid diagnostics. Thyroid-test volume rose from 25,200 in 2022 to 36,200 in 2025, while pro forma revenue increased from $20.3 million to $34.8 million, representing a 19.7% compound annual growth rate. The company is developing new molecular tests to assess progression risk for pancreatic cysts and Barrett’s Esophagus and may pursue complementary technologies, products or acquisitions. Interpace is based in Parsippany, New Jersey.